PPARδ is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
==== Shotgun sequencing ==== High throughput shotgun sequencing using tools such as Solexa or Illumina yields approximately 5 million sequence tags per sample of maternal serum. Aneuploid pregnancies such as trisomy were identified when testing at the fourteenth week of gestation. Fetal whole of genome mapping by parental haplotype analysis was completed using sequencing of cffDNA from maternal serum. Pregnant females were studied using a 2-plex massively parallel maternal plasma DNA sequencing and trisomy was diagnosed with z-score greater than 3. The sequencing gave sensitivity of 100 percent, specificity of 97.9 percent, a positive predictive value of 96.6 percent and a negative predictive value of 100 percent.
==== Pharmacokinetics ==== Dronabinol reaches its highest concentration in blood within 1–2 hours of administration. Food intake increases the time and extent of drug absorption, causing a higher drug concentration in blood at a later time. The high lipid solubility of Dronabinol causes its accumulation in fatty organs such as the heart, liver and spleen. Dronabinol is mostly metabolized by CYP2C9 (an enzyme majorly found in the liver) into 11-hydroxy-delta-9-THC, an active molecule that can enter the brain and cause depression or anxiety. More side effects may be seen in patients with diminished CYP2C9 enzyme activity due to the reduced dronabinol metabolism. Dronabinol is majorly eliminated from the body with faeces.
These edicts temporarily banned the slaughter of animals for several months of the year, prohibited fishing in specific sacred lakes, and mandated the release of thousands of caged birds. This represents one of the earliest recorded instances of state-enforced animal welfare and dietary restrictions at the imperial level in Indian history.
Sources: en.wikipedia.org
== Production and effects == Artificial production methods of radionuclides include neutron sources such as nuclear reactors, as well as particle accelerators such as cyclotrons. The radiation from radionuclides generally has a harmful effect on organisms including humans, although low levels of exposure occur naturally. The degree of harm depends on the nature and extent of the radiation (alpha, beta, gamma, or neutron), the amount and nature of exposure (close contact, inhalation or ingestion), and the element's biochemical properties (toxicity). Increased risk of cancer is unavoidable, and worse cases induce cancer, chronic radiation syndrome or acute radiation syndrome. Radionuclides can be used as weapons by the fallout effects of nuclear weapons and by radiological weapons. Radionuclides are used in nuclear medicine for both diagnosis and treatment. The term “theranostics” (or “theragnostics”) refers to the combination of diagnosis and therapy of a disease within a single medical procedure or technique. An imaging tracer made with radionuclides is a radioactive tracer. Radionuclide therapy is a form of radiotherapy. A pharmaceutical drug made with radionuclides is called a radiopharmaceutical.
=== C-2/C-3 nucleophilic addition === Isatin suffers nucleophilic addition on carbonyls at C-2 and C-3 positions. The regioselectivity of the process strongly depends both on the substrate (properties of the substituents on the isatin core, especially those bonded to the nitrogen atom) and the reaction conditions (solvent, temperature etc.). In some cases the nucleophilic addition could be followed by secondary reactions (e.g. cyclization, ring expansion, ring opening etc.)
== History == The War Office developed from the Council of War, an ad hoc grouping of the King and his senior military commanders which managed the Kingdom of England's wars and campaigns. The management of the War Office was directed initially by the Secretary at War, whose role had originated during the reign of King Charles II as the secretary to the Commander-in-Chief of the Army. In the latter part of the 17th century, the office of Commander-in-Chief was vacant for several periods, which left the Secretary at War answering directly to the Sovereign; and thereafter, even when the office of Commander-in-Chief was restored on a more permanent basis, the Secretary at War retained his independence. The department of the Secretary at War was referred to as the 'Warr Office' (sic) from as early as 1694; its foundation has traditionally been ascribed to William Blathwayt, who had accompanied King William III during the Nine Years' War and who, from his appointment as Secretary in 1684, had greatly expanded the remit of his office to cover general day-to-day administration of the Army. After Blathwayt's retirement in 1704, Secretary at War became a political office. In political terms, it was a fairly minor government job (despite retaining a continued right of access to the monarch) which dealt with the minutiae of administration, rather than grand strategy. The Secretary, who was usually a member of the House of Commons, routinely presented the House with the Army Estimates, and occasionally spoke on other military matters as required.
Many carboxylases, including acetyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, propionyl-CoA carboxylase, and pyruvate carboxylase require biotin as a cofactor. These enzymes are involved in various anabolic pathways. In the EC scheme, such carboxylases are mostly classed under EC 6.4.1, ligases “forming carbon-carbon bonds,” or sometimes EC 6.3.4, "Other Carbon—Nitrogen Ligases". Another example is the posttranslational modification of glutamate residues, to γ-carboxyglutamate, in proteins. It occurs primarily in proteins involved in the blood clotting cascade, specifically factors II, VII, IX, and X, protein C, and protein S, and also in some bone proteins. This modification is required for these proteins to function. Carboxylation occurs in the liver and is performed by γ-glutamyl carboxylase (GGCX). GGCX requires vitamin K as a cofactor and performs the reaction in a processive manner. γ-carboxyglutamate binds calcium, which is essential for its activity. For example, in prothrombin, calcium binding allows the protein to associate with the plasma membrane in platelets, bringing it into close proximity with the proteins that cleave prothrombin to active thrombin after injury.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.